News

Under the agreement, Cambrex will manufacture and deliver Phase 3 and pre-launch quantities of the product candidate. Depending on regulatory developments, the timing of completion of capacity expansion

The divested brands include Valtrex, Lamictal, Timentin, Amoxil and Aropax whose total sales were approximately £83m in 2011 and approximately £31m in the first half of 2012. The

SNS01-T met the criteria for Stable Disease in two of the three evaluable patients that comprised first cohort. No drug-related serious adverse events or dose limiting toxicities were

The Phase II trial will be potentially followed by a larger multi-national Phase III study in the US, Europe and India, according to the company. Pluristem chairman, president

The double-blind, dose escalation trial will enrol approximately 150 volunteers with moderate-to-severe HSV-2 infection who are otherwise healthy. The placebo-controlled study is designed to evaluate the safety and

Cordlife Group CEO Jeremy Yee said in recent years Cordlife has successfully brought the benefits of umbilical cord blood banking to numerous people in multiple regions across China.

The acquisition will enable IMS Health’s clients to enhance the speed, efficiency and cost-effectiveness of their trial planning and management activities. As part of the acquisition, IMS will

According to the information received from the contract laboratory that performed the studies, namely, KARD Scientific, FluCide drug candidate designed for oral administration has shown strong efficacy in

With the IND approval, APX001/SSS07 will be studied in clinical trials for the treatment of autoimmune and inflammatory diseases. Apexigen president and CEO Dr. Xiaodong Yang said, "It